Promoter holding
64.27%
AM
Aqmen Medtech Private Limited - Due diligence report
A 360° intelligence report on Aqmen Medtech: trust score, financial health, credit view, compliance, directors, growth and distress signals …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Aqmen Medtech — 360° Intelligence Report
Generated from MCA filings & public records88/100
Trust Score
Low Risk
Aqmen Medtech is assessed as Low Risk with a Trust Score of 88/100. Aqmen Medtech is an active private limited indian non-government company incorporated in 2018, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 22 Jul 2026 from the latest processed filings. Aqmen Medtech Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
88/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 55/100 Moderate
- Liabilities ≈ 38% EBITDA - stretched.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 1 open (7.50 cr) · 1 satisfied (1.00 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 1 | 48.0 cr |
| Hdfc Bank Limited | 1 | 48.0 cr |
Compliance Score: 93/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 85/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| PEDDA MEKALA KULLAYISWAMY REDDY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DEBASIS DUTTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VINAY KUMAR SINGH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUBRAMANIAN SHIVARAMAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| TEJAS SUBRAMANIAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 5 directors on the board.
- No disqualified or deactivated DINs.
- 3 director exit(s) in the last 3 years.
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
16 allotment(s) · 2 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Latest year revenue grew 2.1x.
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
Net margin improved to 61%.
EPFO headcount growing - hiring signal.
Operating for 8 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 38% in a year.
1 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence88/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment75/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 7.50 cr already registered.
- Compliance record supports lending.
Investor view92/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 6 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
28 Jan 2025
Charge satisfied
Hdfc Bank Limited
28 Dec 2024
Charge created
Others - 7.50 cr
29 Sep 2024
Director ceased
SUBRAMANIAN SHIVARAMAN
12 Jan 2024
Director appointed
SUBRAMANIAN SHIVARAMAN (Director)
10 Aug 2023
Director ceased
VINAY KUMAR SINGH
Director ceased
TEJAS SUBRAMANIAN
09 May 2023
Charge created
Hdfc Bank Limited - 1.00 cr
05 Apr 2023
Director appointed
VINAY KUMAR SINGH (Director)
31 Mar 2023
Share transfer (FY 2023)
2941.00000000 shares to AMBATI SURESH BABU HITESH
Share transfer (FY 2023)
69770.00000000 shares to BUDDHADEV MANGALDAS
28 Mar 2023
Director appointed
TEJAS SUBRAMANIAN (Director)
28 Dec 2022
Securities allotted
109434 Preference Shares - 1.51 cr raised
19 Oct 2022
Securities allotted
72711 Preference Shares - 100.00 Lakh raised
10
Key Observations
Auto-generated from the data aboveRevenue grew 1.42 over the last 4 financial year(s).
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
5 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2023 annual return.
Capital has been raised through 16 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Aashapuri Engineering Private Limited | U29268GJ2007PTC050628 | Ahmedabad, Gujarat, India |
| Tbz | U36911MH1986PLC039643 | Mumbai, Maharashtra, India |
| Kp Abrasives Private Limited | U36100DL2009PTC187883 | New Delhi, Delhi, India |
| Pranali Cement Pipes Private Limited | U26940MH2006PTC161523 | Borivali West, Maharashtra, India |
| M S Granimarmo Private Limited | U14200RJ2013PTC044489 | Jaipur, Rajasthan, India |
| Garg Granites Pvt. Ltd | U14102RJ1992PTC006873 | 4,Ana Sagarlink Road,Ajmer, Rajasthan, India |
| Rasoi Group | U25190WB1905PLC001594 | Saltlake, West Bengal, India |
| Dolly Exim Private Limited | U17299MH1994PTC080539 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Aqmen Medtech before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Aqmen Medtech: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Aqmen Medtech - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 88/100, distress signals and MSME payment-delay disclosures - know whether Aqmen Medtech pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Aqmen Medtech - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Aqmen Medtech an active company?
Aqmen Medtech has MCA status “Active” with a compliance score of 93/100 (Low Risk).
Is Aqmen Medtech financially healthy?
Aqmen Medtech has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.
Should I do business with Aqmen Medtech?
Its overall Trust Score is 88/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Aqmen Medtech?
Promoters hold a minority stake - exact percentages are in the full report. 5 active director(s) are on record.
Does Aqmen Medtech have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.
Is Aqmen Medtech up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).
Is it risky to lend to Aqmen Medtech?
Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
